Serum Zonulin Testing for “Leaky Gut”: What It Really Shows (and What It Doesn’t)

Summary Serum and stool “zonulin” tests are widely marketed as direct measures of intestinal permeability (“leaky gut”). Research suggests zonulin biology is real and relevant to tight junction regulation, especially in celiac disease, but commonly used commercial assays may not measure true zonulin reliably and often do not correlate well with validated permeability tests. Here’s what the science—and its limits—actually say.

What is zonulin and why does it matter?

• Zonulin is a human protein that modulates tight junctions between intestinal epithelial cells, transiently loosening the barrier to regulate antigen trafficking. (Evidence: strong; Fasano, Physiological Reviews 2011; Ann N Y Acad Sci 2012)
• Gliadin (a component of gluten) can trigger zonulin release by binding CXCR3 on enterocytes and immune cells, activating a MyD88-dependent pathway that increases permeability—most clearly in celiac disease. (Evidence: strong; Lammers et al., PLoS One 2011)
• Elevated zonulin signaling has been observed in conditions with barrier dysfunction such as active celiac disease and possibly type 1 diabetes, though causality vs. association varies by condition. (Evidence: moderate; reviews by Fasano 2012; Camilleri, Neurogastroenterol Motil 2019)

What a zonulin test claims to measure

• Serum or stool zonulin assays are marketed to reflect tight junction status and, by extension, “leaky gut.” (Evidence: emerging; market claims not uniformly validated)
• In principle, higher circulating zonulin should parallel increased paracellular permeability; however, practical measurement issues complicate this. (Evidence: moderate; Camilleri 2019)

Key problem: Not all “zonulin” assays measure zonulin

• Independent analyses have reported that some widely used commercial ELISAs detect proteins related to the haptoglobin family or complement factors (e.g., properdin) rather than pre-haptoglobin 2 (the protein identified as zonulin). This raises concerns about specificity. (Evidence: moderate-to-strong; Ajamian et al., Sci Rep 2019; Scheffler et al., PLoS One 2018/2020)
• Measured “zonulin” with these kits often correlates more with systemic inflammation than with established permeability metrics, suggesting off-target detection. (Evidence: moderate; Ajamian 2019; Camilleri 2019)

Does serum or stool zonulin reflect intestinal permeability?

• Agreement with validated permeability tests is inconsistent. Studies comparing serum “zonulin” to lactulose/mannitol (L/M) or lactulose/rhamnose (L/R) ratios report weak or no correlation in many cohorts. (Evidence: moderate; Camilleri 2019 review)
• In celiac disease, zonulin pathway activation is well documented, and levels can be higher during active disease; however, zonulin alone is not sufficient for diagnosis or monitoring. (Evidence: strong for pathway; moderate for clinical utility; Fasano 2012; Camilleri 2019)
• In IBS, IBD, and metabolic disease, reports of elevated “zonulin” are mixed and often confounded by assay specificity and systemic inflammation. (Evidence: moderate; Camilleri 2019)

What conventional medicine accepts vs. what’s debated

• Accepted: The intestinal barrier is dynamic, and tight junction regulation is central to gut-immune crosstalk. Barrier dysfunction features in conditions such as celiac disease and IBD and in subsets of IBS. (Evidence: strong; multiple reviews and mechanistic studies)
• Debated: The clinical utility of serum/stool zonulin testing in individual patients. Major reviews conclude assays are not standardized, and routine zonulin testing is not recommended to diagnose “leaky gut.” (Evidence: moderate; Camilleri, Neurogastroenterol Motil 2019; expert commentaries)

Better-supported ways to assess permeability (primarily in research)

• Sugar probe tests (e.g., lactulose/mannitol or lactulose/rhamnose): Noninvasive oral probes with urinary recovery ratios reflect small-intestinal paracellular permeability. Results are influenced by gastric emptying, small-bowel transit, renal function, and timing, so standardized protocols matter. (Evidence: strong for research utility; Bjarnason et al., Gut 1995; van Wijck et al., Am J Physiol 2013)
• Additional biomarkers: Intestinal fatty acid binding protein (I-FABP; enterocyte injury) and LPS-binding protein (LBP; endotoxemia response) are used in research as adjuncts, not stand-alone diagnostics. (Evidence: moderate; multiple translational studies)
• Clinical context remains essential: In established diseases like celiac disease and IBD, diagnosis and monitoring rely on serology, endoscopy/biopsy, imaging, and symptom assessment rather than zonulin testing. (Evidence: strong; clinical guidelines)

Where zonulin biology may still inform care

• Celiac disease: Gliadin-induced zonulin release helps explain why strict gluten exclusion restores barrier integrity. Zonulin antagonists are under investigation but are not standard of care. (Evidence: strong for mechanism; emerging for therapeutics)
• Exercise/heat stress and NSAID use: These stressors can transiently increase permeability via tight junction effects; zonulin may contribute among other pathways. (Evidence: moderate; van Wijck 2013; exercise/NSAID literature)

Interventions that may influence barrier function (context, not prescriptions)

• L-glutamine: In IBS-D, a randomized trial reported improved permeability (lower L/M ratio) and symptom reduction compared with placebo. (Evidence: moderate; Zhou et al., Clin Transl Gastroenterol 2019)
• Zinc carnosine (polaprezinc): Human trials suggest support for mucosal integrity and reduced NSAID-related small-bowel injury and permeability. (Evidence: moderate; Mahmood et al., Aliment Pharmacol Ther 2007; Japanese clinical data)
• Bovine colostrum: RCTs in athletes and NSAID challenge models reported attenuation of permeability increases and gut injury markers. (Evidence: moderate; Playford et al., Gut 2001; exercise model trials)
• Dietary patterns: For celiac disease, strict gluten avoidance normalizes permeability; in IBD, anti-inflammatory dietary strategies may support mucosal healing alongside medical therapy. (Evidence: strong for celiac; moderate for IBD adjunctive nutrition)
• Traditional demulcents and broths: Slippery elm (Ulmus rubra), aloe vera gel, and bone broth are traditionally used to soothe the GI lining. Small clinical studies suggest aloe may help mild-to-moderate ulcerative colitis, but evidence remains limited for barrier outcomes. (Evidence: emerging/traditional; Langmead et al., Aliment Pharmacol Ther 2004; herbal demulcent tradition in Western herbalism)
• Traditional Chinese Medicine (TCM): Formulas aimed at “harmonizing the middle jiao” and strengthening the spleen–stomach system (e.g., Ban Xia Xie Xin Tang–type approaches) are traditionally used for digestive integrity; modern trials are preliminary. (Evidence: traditional/emerging; TCM gastroenterology reviews)

Practical takeaways about zonulin testing

• Zonulin biology is real and mechanistically important, especially in celiac disease. (Evidence: strong)
• Current commercial serum/stool “zonulin” assays show specificity issues and inconsistent correlation with validated permeability tests. Routine use to diagnose “leaky gut” is not supported. (Evidence: moderate)
• When barrier dysfunction is suspected clinically, established disease-specific diagnostics and, in research settings, standardized sugar probe tests provide more interpretable data than standalone zonulin assays. (Evidence: strong for standard diagnostics; strong for research utility of sugar probes)
• Supportive strategies for barrier health should be individualized, evidence-informed, and integrated with conventional care; no single biomarker currently directs therapy. (Evidence: strong consensus)

How this bridges traditional and modern views Traditional systems have long emphasized maintaining a resilient gut lining through soothing botanicals and easily digested broths, while modern biology identifies tight junctions, zonulin, and other regulators that mechanistically justify this emphasis. The convergence—care for the mucosa and reduce irritants—remains sensible, even as the field works toward better biomarkers.

Bottom line

• Zonulin regulates tight junctions, and dysregulation can increase intestinal permeability. (Evidence: strong)
• However, many commercial zonulin tests may not measure authentic zonulin reliably and often do not reflect true permeability status. (Evidence: moderate-to-strong)
• For clinical decision-making, rely on established diagnostics for specific diseases and consider permeability testing primarily in research contexts. (Evidence: strong)
• Interventions such as L-glutamine, zinc carnosine, and bovine colostrum may help support barrier integrity in select contexts, while traditional demulcent herbs and broths align with this goal; overall, evidence ranges from moderate to emerging and should complement—not replace—conventional care. (Evidence: moderate to emerging)

Selected references

• Fasano A. Zonulin and its regulation of intestinal barrier function. Physiol Rev 2011; Ann N Y Acad Sci 2012.
• Lammers KM et al. Gliadin induces zonulin release via CXCR3 signaling. PLoS One 2011.
• Camilleri M. Leaky gut: mechanisms, measurement, and clinical implications in humans. Neurogastroenterol Motil 2019.
• Ajamian M et al. Commercial zonulin ELISA detects complement proteins, not pre-HP2. Sci Rep 2019.
• Scheffler L et al. Popular zonulin ELISA lacks specificity for zonulin. PLoS One 2018/2020.
• Bjarnason I et al. Intestinal permeability testing overview. Gut 1995.
• van Wijck K et al. Exercise/heat stress and permeability (L/R test). Am J Physiol Gastrointest Liver Physiol 2013.
• Zhou Q et al. Glutamine reduces permeability and symptoms in IBS-D. Clin Transl Gastroenterol 2019.
• Playford RJ et al. Bovine colostrum protects against NSAID-induced gut injury. Gut 2001.
• Langmead L et al. Aloe vera in mild-to-moderate ulcerative colitis. Aliment Pharmacol Ther 2004.